BioNTech CAR-T manufacturing change leads to fresh data with vaccine combo, with registrational trial plans: #ESMO23
MADRID — BioNTech is back with new data to support its BNT211 program in solid tumors after a manufacturing tweak. The company is now reviewing plans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.